Heart Disease Trial, Recruiting NCT06255769 Sponsor: Qilu Hospital of Shandong University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06255769
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have chest pain or other symptoms suggesting reduced blood flow to the heart, and whose coronary artery imaging (either a catheter-based test or a CT scan) has shown that any narrowing in the arteries is less than 70% (not severely blocked)
  • People who have signed a consent form agreeing to take part

Who may not be able to join:

  • People who have certain medical reasons that make a specific type of nuclear heart scan (called a stress myocardial perfusion scan) unsafe for them — including a heart attack within the past 48 hours, severe narrowing of the main heart artery, asthma, or a known allergy to a medicine called adenosine
  • People who have a type of enlarged heart disease not caused by reduced blood flow, a thickened heart muscle condition, or moderate to severe heart valve disease
  • People whose blood pressure is dangerously low (below 90 mmHg at the top reading), who require medicines to maintain blood pressure, or who have certain unresolved abnormal heart rhythms or significant heart electrical conduction problems
  • People with severely reduced kidney function (eGFR below 30 ml/min) or who are currently on dialysis
  • People with a cancer diagnosis where survival is expected to be less than one year
  • People who are pregnant or breastfeeding
  • People who are unable to be placed inside the trial's heart-scanning device (MCG), including those with metal implants that would interfere with the scan, or anyone the trial doctors consider unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yuguo Chen, Professor, Qliu Hospital of Shandong University

Phone: 0086-0531-82165398

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
12 February 2024
Est. completion
31 October 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Efficacy of MCG to detect myocardial ischemia using SPECT as a reference standard.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov